First Clinical Trial Results of Xcellerex, Inc. Inactivated Vaccine Against Yellow Fever Published in The New England Journal of Medicine

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc., a leader in rapid deployment, single-use biomanufacturing solutions, today announced positive results of a Phase I clinical trial of its investigational vaccine against yellow fever virus, XRX-001. In the study, the vaccine was well tolerated and induced neutralizing antibodies in 100 percent of subjects receiving a high dose and 88 percent receiving a low dose. The results are published in the April 7, 2011 edition of the New England Journal of Medicine.

Back to news